Jiangsu Recbio Technology Co., Ltd. (FRA:G93)

Market Cap	266.90M -27.4%
Revenue (ttm)	63.40K -76.7%
Net Income	-62.05M
EPS	-0.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	990
Open	0.3720
Previous Close	0.3700
Day's Range	0.3720 - 0.3720
52-Week Range	0.0635 - 0.7550
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 466
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: G93

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error